Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
| Autor: | N. Mikhailova, Kai Hübel, Nina Worel, Zdenek Koristek, Francesco Lanza, Mahmoud Aljurf, Roberto M. Lemoli, Gabor Mikala, Laurent Garderet, J. F. Apperley, Grzegorz W. Basak, N Kröger, Patrick Wuchter, Michael W. Kattan, Harry C. Schouten, Arnon Nagler, Ali Bazarbachi, Ian H Gabriel, D Selleslag, K. Douglas, Ozren Jakšić, Anna Sureda, Christian Chabannon, R. F. Duarte, Stefan Suciu, Catarina Geraldes, L. Mendeleeva, M. Mohty |
|---|---|
| Přispěvatelé: | MUMC+: MA Hematologie (9), Interne Geneeskunde, RS: GROW - Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Melphalan medicine.medical_specialty Lymphoma medicine.medical_treatment Transplantation Autologous NO Internal medicine medicine Humans Hematopoietic Stem Cell Mobilization Multiple myeloma Transplantation Chemotherapy business.industry Hematology medicine.disease Surgery Fludarabine Europe Regimen Apheresis Multiple Myeloma business Autologous medicine.drug |
| Zdroj: | Bone Marrow Transplantation, 49(7), 865-872. Nature Publishing Group |
| ISSN: | 0268-3369 |
| DOI: | 10.1038/bmt.2014.39 |
| Popis: | Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|